FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SABBY MANAGEMENT, LLC 		2. Issuer Name and Ticker or Trading Symbol

Rosetta Genomics Ltd. [ ROSG ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

10 MOUNTAINVIEW ROAD, SUITE 205 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/12/2018
(Street)

UPPER SADDLE RIVER, NJ 07458
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    20373   A $0.4199   595094   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    454   A $0.401   595548   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    2604   A $0.4199   598152   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    11521   A $0.41   609673   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    21800   A $0.4117   631473   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    24600   A $0.4185   656073   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    24162   A $0.4186   680235   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    10605   A $0.4189   690840   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    12390   A $0.4101   703230   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/12/2018     P    10000   A $0.42   713230   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/13/2018     P    30990   A $0.4203   744220   I   (1) (2) See Footnotes   (1) (2)
ADR Shares (each one equal to 2 ordinary shares)   3/13/2018     P    6329   A $0.42   750549   I   (1) (2) See Footnotes   (1) (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  This Form 4 is being filed by Sabby Healthcare Master Fund, Ltd. ("SHMF"), Sabby Volatility Warrant Master Fund, Ltd. ("SVWMF"), Sabby Management, LLC ("Advisor") and Hal Mintz. Advisor is the investment manager of SHMF and SVWMF. Mr. Mintz is the manager of Advisor.
(2)  The amounts reported herein reflect the entire amount of Issuer's ADR shares held by SHMF and SVWMF as of each transaction date. Each of Advisor and Mr. Mintz disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of its/his pecuniary interest therein, and this report shall not be deemed as admission that either Advisor or Mr. Mintz is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SABBY MANAGEMENT, LLC
10 MOUNTAINVIEW ROAD
SUITE 205
UPPER SADDLE RIVER, NJ 07458
X

Sabby Healthcare Master Fund, Ltd.
C/O SABBY MANAGEMENT, LLC
10 MOUNTAINVIEW ROAD, SUITE 205
UPPER SADDLE RIVER, NJ 07458
X


Signatures
/s/ Robert Grundstein, COO and General Counsel of Sabby Management, LLC 3/14/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Rosetta Genomics (CE) (USOTC:ROSGQ)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Rosetta Genomics (CE) 차트를 더 보려면 여기를 클릭.
Rosetta Genomics (CE) (USOTC:ROSGQ)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Rosetta Genomics (CE) 차트를 더 보려면 여기를 클릭.